How to Effectively Manage a Product Recall - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

How to Effectively Manage a Product Recall
The authors group key actions to consider when conducting a product recall and discuss how to execute them carefully and thoroughly.


Pharmaceutical Technology
Volume 35, Issue 1

Not too many words in the English language cause heads to turn and skin to crawl like the word recall. Product recalls are situations that all companies try their best to avoid, but if a recall is necessary, how does a company effectively develop and implement a plan without undue delay and confusion?

The actions to consider when conducting a product recall can be grouped into seven areas. Each of these areas should be executed carefully and thoroughly in order to effectively manage the recall activity. This article discusses the following seven recall areas: conducting a health-hazard assessment, planning a course of action, contacting the US Food and Drug Administration, getting the word out, the importance of keeping accurate records, staying focused, and when is the recall actually ended?

What is a recall and when is it necessary?

To effectively manage a product recall, it is important to first understand what constitutes a recall and when it is necessary. Simply put, a recall is necessary when a product is found to be defective in some way, and removing it from the market is the only way to ensure consumer safety. Recalls can be either voluntary (i.e., undertaken by the manufacturer or distributor at any time) or can be initiated at the request of FDA (usually reserved for urgent and serious situations).

A recall usually results from one or a combination of the following situations:

1. Company discovery: A company discovers, through its own routine testing program, that a product lot does not meet one or more of the specifications that are established for that product.

2. Customer complaint: Often a problem is discovered from customer complaints.

3. FDA observation: Recalls can also be necessitated as a result of an observation made by FDA during an inspection. Significant compliance deficiencies noted by FDA can result in a company having to recall some or all of its drug lots.

Conducting a health-hazard assessment


Table I: Health-hazard assessment elements.
Not all product failures that are discovered by a company lead to a recall. To determine whether a recall may be necessary, the impact that the failure may have on the safety and efficacy of the product must be evaluated. This is done by conducting a health-hazard assessment. By performing and documenting the hazard-assessment, conclusions can be drawn as to the chance that a consumer can be harmed by using the product in question. Often, companies use product experts to consult in the assessment. The type of expert will depend on the nature of the product, (e.g., medical doctors, pharmacologists, and toxicologists). A summary of the basic elements that should be included in a health-hazard assessment are listed in Table I. If the overall conclusion is that there are or may be harmful effects from the failure, a recall will be necessary and removing the product from the marketplace becomes the top priority.


Table II: Example of a health-hazard assessment.
An example of a situation when a recall was determined to be unnecessary was observed in a solid oral-dosage form plant. Table II shows an example of the health-hazard assessment that was conducted and how the ultimate conclusion was reached.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here